Adverse Outcomes Increased With Long-Term Inhaled Corticosteroids in COPD

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on March 28, 2025.

By Elana Gotkine HealthDay Reporter

FRIDAY, March 28, 2025 -- For patients with chronic obstructive pulmonary disorder (COPD), long-term inhaled corticosteroid (ICS) treatment is associated with increased rates of adverse composite and specific individual outcomes, according to a study published in the March/April issue of the Annals of Family Medicine.

Wilson D. Pace, M.D., from DARTNet Institute in Aurora, Colorado, and colleagues examined electronic health record data for individuals older than 45 years with COPD to assess long-term ICS risks. The prevalent cohort had a COPD diagnosis any time during the observation period (318,385 individuals), and the inception cohort had a COPD diagnosis after entry into the database (209,062 individuals). A composite outcome of any new diagnosis of type 2 diabetes, cataracts, pneumonia, osteoporosis, or nontraumatic fracture and recurrent event outcomes of repeated pneumonia or nontraumatic fracture were compared for long- versus short-term ICS exposure (>24 months versus <4 months).

The researchers found that the composite dichotomous outcome was significantly greater for long- versus short-term ICS use for both the prevalent and inception cohorts (hazard ratios, 2.65 and 2.60, respectively). The absolute risk difference of the composite outcome was 20.26 percent for the inception cohort, with a number needed to harm of five. For recurrent pneumonia and recurrent fracture, the hazard ratios were significantly increased in the prevalent and inception cohorts (hazard ratios, 2.88 and 2.85 for pneumonia, respectively; 1.77 and 1.57 for fracture, respectively).

"The clinical use of and indications for ICS therapy in COPD should be carefully considered for each individual before initiation of long-term ICS therapy," the authors write.

Several authors disclosed ties to the pharmaceutical industry, and the study was funded by a research grant from Boehringer Ingelheim.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-03-29 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords